n5

Laninamivir (R 125489) is an effective inhibitor of influenza neuraminidase (NA) (IC50s: 0.90 nM, 1.83 nM, and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively).

N1,N5,N10,N14-Tetra-trans-p-coumaroylspermine is a useful organic compound for research related to life sciences and the catalog number is T130733.

N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide is an analogue of TT3 . TT3 is an ionizable lipid-like materials for mRNA and CRISPR Cas9 delivery [1] [2] .

Calcium N5-methyltetrahydrofolate (NSC-173328) is the calcium salt of levomefolic acid, which has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers

N1,N5,N10-(E)-tri-p-coumaroylspermidine shows free radical-scavenging activity.

N4-Desmethyl-N5-Methyl wyosine is a nucleoside derivative and a naturally modified ribonucleoside, characterized as a bi- tri-cyclic nucleoside.

N1,N5-Bis-boc-spermidine is a linker containing one amino group and two Boc-protected amino groups. The amino group can react with carboxylic acids, activated NHS esters, and carbonyls (such as ketones and aldehydes). Boc groups can be removed under mild acidic conditions to form free amines.

CSN5i-3 is a potent, selective, and orally available inhibitor of the proteolytic subunit of the CSN complex, CSN5. It inhibits CSN-catalyzed Cul1 deneddylation with an IC50 value of 5.8 nM. CSN5i-3 has a killing effect on a variety of cancer cells and can be used as an anticancer drug. [2]

McN5691 (RWJ26240) is a voltage-dependent calcium channel blocker with antihypertensive activity that can be used in the study of diseases caused by vascular smooth muscle abnormalities.

(R)-CSN5i-3 is CSN5i-3 of the R configuration.

KRN5 is an effective inhibitor of NFAT5 with an IC50 of 750 nM and can be used in studies about chronic arthritis.

QN523 represents a novel scaffold with drug-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 shows significant in vivo efficacy in a pancreatic cancer xenograft model. Autophagy is a major mechanism of action.

CAN508 is a potent ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It also competitively inhibits Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 μM and 20 μM, respectively. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. [Antitumor activity.]

KUN56321 (3H-Naphth[1,2-d]imidazole, 2-(4-bromophenyl)-3-phenyl-) is a luminescent agent. The application of KUN56321 comprises: coating the film of KUN56321 onto hole transport layer or electron transport layer of ITO glass by vacuum evapn.coating the hole transport layer or electron transport layer onto the film by evapn., prepg. metal electrode by evapn. KUN56321 showed the capability to improve light emitting efficiency and reducing drive voltage in org. light- emitting device and display device.

MUN57694 is an inhibitor of 26S proteasome.

[Orn5]-URP acetate is an effective and selective Urotensin-II receptor (UT) antagonist (pEC50 = 7.24). [Orn5]-URP exhibits no agonist activity.

MN58b is a selective inhibitor of choline kinase α (CHKα).

SN50 is a cell permeable NF-κB translocation inhibitor.

SN50 acetate is a cell permeable inhibitor of NF-κB translocation.

GLN51108 is a synthetic porphyrin derivative primarily used to initiate artificial photosynthesis and induce apoptosis. Additionally, GLN51108 is also employed in catalytic heterogeneous oxidation.

4-Hydroxy-3-methoxymethylamphetamine (HMMA) is an active metabolite of 3,4-methylenedioxy-N-methylamphetamine (MDMA). Compared to MDMA, it exhibits slightly stronger stimulant effects.

CSN5-IN-2 (Compound 31) is a CSN5 inhibitor with an IC50 of 0.36 μM. It increases Cullin 1 neddylation levels in cancer cells and downregulates the expression of RAD51 and PD-L1. CSN5-IN-2 exhibits antitumor activity, which is enhanced when used in combination with Talazoparib.

Tandutinib is an effective antagonist for FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit. Tandutinib potently inhibited the activity of FLT3, PDGFR, and c-Kit (IC50: ~200 nM).

RKN5755 is a selective activated fibroblasts inhibitor that acts by inhibiting the enhanced migration of fibroblasts cocultured with cancer cells by binding to β-arrestin1 and interfering with β-arrestin1-mediated cofilin signaling pathways.